Sunday, 25 February 2024

Australia's most trusted
source of pharma news

Sunday, 25 February 2024
Listen to this story 

Why this pharma is sitting pretty

Posted 9 February 2024 AM

Winning earlier-than-expected blockbuster status for one of its products in 2023 seems to have set GSK on a roll.

The company's RSV vaccine, Arexvy, launched last year in the US with expectations of high sales, but not so soon. In its third quarter earnings release, GSK predicted sales of Arexvy would be between $1.7 billion and $1.9 billion for the full year. In fact, the vaccine roared to blockbuster status by pulling in $2.4 billion for 2023.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (16)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (7)

Other (26)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.